文献速递临床试验与 GCP流行病学与生物统计

强化生活方式干预对2型糖尿病患者血糖控制的影响:一项随机临床试验

Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

在丹麦两个地区开展的单中心、评估者盲法随机试验,纳入98例非胰岛素依赖且病程小于10年的2型糖尿病患者,按2:1随机分为生活方式组(n=64)和标准治疗组(n=34)。12个月随访时,生活方式组HbA1c从6.65%降至6.34%,标准治疗组从6.74%降至6.66%,组间变化差异为-0.26%(95%CI,-0.52%至-0.01%),未达到预设的等效标准(P=.15)。生活方式组47例(73.5%)减少降糖药物,标准治疗组9例(26.4%),差异为47.1个百分点(95%CI,28.6-65.3)。

要点

  • 在病程小于10年的2型糖尿病患者中,强化生活方式干预12个月的HbA1c变化未达到预设等效标准。
  • 生活方式组HbA1c从6.65%降至6.34%,标准治疗组从6.74%降至6.66%,组间变化差异-0.26%(95%CI,-0.52%至-0.01%)。
  • 生活方式组73.5%(47例)减少降糖药物,标准治疗组26.4%(9例),差异47.1个百分点(95%CI,28.6-65.3)。

核心结论

  • 在病程小于10年的2型糖尿病成人中,与标准治疗相比,生活方式干预带来的血糖控制变化未达到等效标准,但方向与获益一致。
  • 作者指出需要进一步研究评估优效性以及结果的普遍性和持久性。

研究设计与样本

  • 随机、评估者盲法、单中心研究,在丹麦西兰大区和首都大区开展(2015年4月至2016年8月)。
  • 纳入98例非胰岛素依赖且诊断为2型糖尿病小于10年的成人参与者,按2:1(按性别分层)随机分配至生活方式组(n=64)或标准治疗组(n=34)。
  • 所有参与者均接受标准治疗,包括个体咨询和标准化、盲法、目标驱动的药物治疗;生活方式干预额外包括每周5至6次有氧训练(每次30-60分钟),其中2至3次结合抗阻训练,并接受旨在使体重指数达到25或以下的饮食计划。
  • 随访12个月;主要结局为从基线至12个月随访的HbA1c变化,基于意向性治疗人群预设等效界值为±0.4%;对降糖药物减少这一次要结局进行优效性分析。

主要发现

  • 98例随机参与者平均年龄54.6岁(SD,8.9),女性47例(48%),平均基线HbA1c为6.7%;93例完成试验。
  • 从基线至12个月随访,生活方式组平均HbA1c从6.65%变为6.34%,标准治疗组从6.74%变为6.66%,组间变化差异为-0.26%(95%CI,-0.52%至-0.01%),未达到等效标准(P=.15)。
  • 降糖药物减少发生于生活方式组47例(73.5%)和标准治疗组9例(26.4%),差异为47.1个百分点(95%CI,28.6-65.3)。
  • 生活方式组发生32例不良事件(最常见为肌肉骨骼疼痛或不适和轻度低血糖),标准治疗组发生5例。

局限性

  • 原文指出需要进一步研究评估优效性以及结果的普遍性和持久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unclear whether a lifestyle intervention can maintain glycemic control in patients with type 2 diabetes. OBJECTIVE: To test whether an intensive lifestyle intervention results in equivalent glycemic control compared with standard care and, secondarily, leads to a reduction in glucose-lowering medication in participants with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized, assessor-blinded, single-center study within Region Zealand and the Capital Region of Denmark (April 2015-August 2016). Ninety-eight adult participants with non-insulin-dependent type 2 diabetes who were diagnosed for less than 10 years were included. Participants were randomly assigned (2:1; stratified by sex) to the lifestyle group (n = 64) or the standard care group (n = 34). INTERVENTIONS: All participants received standard care with individual counseling and standardized, blinded, target-driven medical therapy. Additionally, the lifestyle intervention included 5 to 6 weekly aerobic training sessions (duration 30-60 minutes), of which 2 to 3 sessions were combined with resistance training. The lifestyle participants received dietary plans aiming for a body mass index of 25 or less. Participants were followed up for 12 months. MAIN OUTCOMES AND MEASURES: Primary outcome was change in hemoglobin A1c (HbA1c) from baseline to 12-month follow-up, and equivalence was prespecified by a CI margin of ±0.4% based on the intention-to-treat population. Superiority analysis was performed on the secondary outcome reductions in glucose-lowering medication. RESULTS: Among 98 randomized participants (mean age, 54.6 years [SD, 8.9]; women, 47 [48%]; mean baseline HbA1c, 6.7%), 93 participants completed the trial. From baseline to 12-month follow-up, the mean HbA1c level changed from 6.65% to 6.34% in the lifestyle group and from 6.74% to 6.66% in the standard care group (mean between-group difference in change of -0.26% [95% CI, -0.52% to -0.01%]), not meeting the criteria for equivalence (P = .15). Reduction in glucose-lowering medications occurred in 47 participants (73.5%) in the lifestyle group and 9 participants (26.4%) in the standard care group (difference, 47.1 percentage points [95% CI, 28.6-65.3]). There were 32 adverse events (most commonly musculoskeletal pain or discomfort and mild hypoglycemia) in the lifestyle group and 5 in the standard care group. CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes diagnosed for less than 10 years, a lifestyle intervention compared with standard care resulted in a change in glycemic control that did not reach the criterion for equivalence, but was in a direction consistent with benefit. Further research is needed to assess superiority, as well as generalizability and durability of findings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02417012.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Johansen MY, MacDonald CS, Hansen KB, et al. Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017. PMID: 28810024. doi:10.1001/jama.2017.10169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。